REFERENCES
1. Chandra RA, Keane FK, Voncken FEM, Thomas CR. Contemporary radiotherapy: present and future. Lancet 2021;398:171-84.
2. Jackson SP, Bartek J. The DNA-damage response in human biology and disease. Nature 2009;461:1071-8.
3. Hauer MH, Gasser SM. Chromatin and nucleosome dynamics in DNA damage and repair. Genes Dev 2017;31:2204-21.
4. Beucher A, Birraux J, Tchouandong L, et al. ATM and Artemis promote homologous recombination of radiation-induced DNA double-strand breaks in G2. EMBO J 2009;28:3413-27.
5. Huertas P. DNA resection in eukaryotes: deciding how to fix the break. Nat Struct Mol Biol 2010;17:11-6.
6. Symington LS, Gautier J. Double-strand break end resection and repair pathway choice. Annu Rev Genet 2011;45:247-71.
7. Sallmyr A, Tomkinson AE. Repair of DNA double-strand breaks by mammalian alternative end-joining pathways. J Biol Chem 2018;293:10536-46.
8. Callen E, Di Virgilio M, Kruhlak MJ, et al. 53BP1 mediates productive and mutagenic DNA repair through distinct phosphoprotein interactions. Cell 2013;153:1266-80.
9. Escribano-Díaz C, Orthwein A, Fradet-Turcotte A, et al. A cell cycle-dependent regulatory circuit composed of 53BP1-RIF1 and BRCA1-CtIP controls DNA repair pathway choice. Mol Cell 2013;49:872-83.
10. Chapman JR, Barral P, Vannier JB, et al. RIF1 is essential for 53BP1-dependent nonhomologous end joining and suppression of DNA double-strand break resection. Mol Cell 2013;49:858-71.
11. Di Virgilio M, Callen E, Yamane A, et al. Rif1 prevents resection of DNA breaks and promotes immunoglobulin class switching. Science 2013;339:711-5.
12. Zimmermann M, Lottersberger F, Buonomo SB, Sfeir A, de Lange T. 53BP1 regulates DSB repair using Rif1 to control 5’ end resection. Science 2013;339:700-4.
13. Xu G, Chapman JR, Brandsma I, et al. REV7 counteracts DNA double-strand break resection and affects PARP inhibition. Nature 2015;521:541-4.
14. Boersma V, Moatti N, Segura-Bayona S, et al. MAD2L2 controls DNA repair at telomeres and DNA breaks by inhibiting 5’ end resection. Nature 2015;521:537-40.
15. Noordermeer SM, Adam S, Setiaputra D, et al. The shieldin complex mediates 53BP1-dependent DNA repair. Nature 2018;560:117-21.
16. Mirman Z, Lottersberger F, Takai H, et al. 53BP1-RIF1-shieldin counteracts DSB resection through CST- and Polα-dependent fill-in. Nature 2018;560:112-6.
17. Dev H, Chiang TW, Lescale C, et al. Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells. Nat Cell Biol 2018;20:954-65.
18. Gupta R, Somyajit K, Narita T, et al. DNA repair network analysis reveals shieldin as a key regulator of NHEJ and PARP inhibitor sensitivity. Cell 2018;173:972-988.e23.
19. Chapman JR, Sossick AJ, Boulton SJ, Jackson SP. BRCA1-associated exclusion of 53BP1 from DNA damage sites underlies temporal control of DNA repair. J Cell Sci 2012;125:3529-34.
20. Nakamura K, Saredi G, Becker JR, et al. H4K20me0 recognition by BRCA1-BARD1 directs homologous recombination to sister chromatids. Nat Cell Biol 2019;21:311-8.
21. Bunting SF, Callén E, Wong N, et al. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell 2010;141:243-54.
22. Zhang F, Ma J, Wu J, et al. PALB2 links BRCA1 and BRCA2 in the DNA-damage response. Curr Biol 2009;19:524-9.
23. Wei S, Li C, Yin Z, et al. Histone methylation in DNA repair and clinical practice: new findings during the past 5-years. J Cancer 2018;9:2072-81.
24. Botuyan MV, Lee J, Ward IM, et al. Structural basis for the methylation state-specific recognition of histone H4-K20 by 53BP1 and Crb2 in DNA repair. Cell 2006;127:1361-73.
25. Wilson MD, Benlekbir S, Fradet-Turcotte A, et al. The structural basis of modified nucleosome recognition by 53BP1. Nature 2016;536:100-3.
26. Greeson NT, Sengupta R, Arida AR, Jenuwein T, Sanders SL. Di-methyl H4 lysine 20 targets the checkpoint protein Crb2 to sites of DNA damage. J Biol Chem 2008;283:33168-74.
27. Wu W, Nishikawa H, Fukuda T, et al. Interaction of BARD1 and HP1 is required for BRCA1 retention at sites of DNA damage. Cancer Res 2015;75:1311-21.
28. Husmann D, Gozani O. Histone lysine methyltransferases in biology and disease. Nat Struct Mol Biol 2019;26:880-9.
29. Long Q, Liu Z, Gullerova M. Sweet melody or jazz? Transcription around DNA double-strand breaks. Front Mol Biosci 2021;8:655786.
30. Pessina F, Giavazzi F, Yin Y, et al. Functional transcription promoters at DNA double-strand breaks mediate RNA-driven phase separation of damage-response factors. Nat Cell Biol 2019;21:1286-99.
31. Pryde F, Khalili S, Robertson K, et al. 53BP1 exchanges slowly at the sites of DNA damage and appears to require RNA for its association with chromatin. J Cell Sci 2005;118:2043-55.
32. Shanbhag NM, Rafalska-Metcalf IU, Balane-Bolivar C, Janicki SM, Greenberg RA. ATM-dependent chromatin changes silence transcription in cis to DNA double-strand breaks. Cell 2010;141:970-81.
33. Faucher D, Wellinger RJ. Methylated H3K4, a transcription-associated histone modification, is involved in the DNA damage response pathway. PLoS Genet 2010;6:e1001082.
34. Moyal L, Lerenthal Y, Gana-Weisz M, et al. Requirement of ATM-dependent monoubiquitylation of histone H2B for timely repair of DNA double-strand breaks. Mol Cell 2011;41:529-42.
35. Mosammaparast N, Kim H, Laurent B, et al. The histone demethylase LSD1/KDM1A promotes the DNA damage response. J Cell Biol 2013;203:457-70.
36. Li X, Liu L, Yang S, et al. Histone demethylase KDM5B is a key regulator of genome stability. Proc Natl Acad Sci U S A 2014;111:7096-101.
37. Gong F, Clouaire T, Aguirrebengoa M, Legube G, Miller KM. Histone demethylase KDM5A regulates the ZMYND8-NuRD chromatin remodeler to promote DNA repair. J Cell Biol 2017;216:1959-74.
38. Bayo J, Tran TA, Wang L, Peña-Llopis S, Das AK, Martinez ED. Jumonji inhibitors overcome radioresistance in cancer through changes in H3K4 methylation at double-strand breaks. Cell Rep 2018;25:1040-1050.e5.
39. Bayley R, Borel V, Moss RJ, et al. H3K4 methylation by SETD1A/BOD1L facilitates RIF1-dependent NHEJ. Mol Cell 2022;82:1924-1939.e10.
40. Higgs MR, Sato K, Reynolds JJ, et al. Histone methylation by SETD1A protects nascent DNA through the nucleosome chaperone activity of FANCD2. Mol Cell 2018;71:25-41.e6.
41. Clouaire T, Rocher V, Lashgari A, et al. Comprehensive mapping of histone modifications at DNA double-strand breaks deciphers repair pathway chromatin signatures. Mol Cell 2018;72:250-262.e6.
42. Nakamura K, Kato A, Kobayashi J, et al. Regulation of homologous recombination by RNF20-dependent H2B ubiquitination. Mol Cell 2011;41:515-28.
43. Moynahan ME, Chiu JW, Koller BH, Jasin M. Brca1 controls homology-directed DNA repair. Mol Cell 1999;4:511-8.
44. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005;434:917-21.
45. Murai J, Huang SY, Das BB, et al. Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 2012;72:5588-99.
46. Robson M, Im SA, Senkus E, et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 2017;377:523-33.
47. Kyo S, Kanno K, Takakura M, et al. Clinical landscape of PARP inhibitors in ovarian cancer: molecular mechanisms and clues to overcome resistance. Cancers (Basel) 2022;14:2504.
49. Bouwman P, Aly A, Escandell JM, et al. 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers. Nat Struct Mol Biol 2010;17:688-95.
50. Begum S, Goula A, Bayley R, Higgs MR. On your marks, get SET(D1A): the race to protect stalled replication forks. Mol Cell Oncol 2018;5:e1511209.
51. Thakar T, Moldovan GL. The emerging determinants of replication fork stability. Nucleic Acids Res 2021;49:7224-38.
52. Guillemette S, Serra RW, Peng M, et al. Resistance to therapy in BRCA2 mutant cells due to loss of the nucleosome remodeling factor CHD4. Genes Dev 2015;29:489-94.
53. Ray Chaudhuri A, Callen E, Ding X, et al. Replication fork stability confers chemoresistance in BRCA-deficient cells. Nature 2016;535:382-7.
54. Rondinelli B, Gogola E, Yücel H, et al. EZH2 promotes degradation of stalled replication forks by recruiting MUS81 through histone H3 trimethylation. Nat Cell Biol 2017;19:1371-8.
55. Song Y, Wu F, Wu J. Targeting histone methylation for cancer therapy: enzymes, inhibitors, biological activity and perspectives. J Hematol Oncol 2016;9:49.
56. Yang L, Jin M, Jeong KW. Histone H3K4 methyltransferases as targets for drug-resistant cancers. Biology (Basel) 2021;10:581.
57. Zhu J, Liu Z, Liang X, et al. A pan-cancer study of KMT2 family as therapeutic targets in cancer. J Oncol 2022;2022:3982226.
58. Fang Y, Liao G, Yu B. LSD1/KDM1A inhibitors in clinical trials: advances and prospects. J Hematol Oncol 2019;12:129.
59. Harris WJ, Huang X, Lynch JT, et al. The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells. Cancer Cell 2012;21:473-87.
60. Kuroda S, Fujiwara T, Shirakawa Y, et al. Telomerase-dependent oncolytic adenovirus sensitizes human cancer cells to ionizing radiation via inhibition of DNA repair machinery. Cancer Res 2010;70:9339-48.
61. Vilar E, Bartnik CM, Stenzel SL, et al. MRE11 deficiency increases sensitivity to poly(ADP-ribose) polymerase inhibition in microsatellite unstable colorectal cancers. Cancer Res 2011;71:2632-42.
62. Wang J, Ding Q, Fujimori H, Motegi A, Miki Y, Masutani M. Loss of CtIP disturbs homologous recombination repair and sensitizes breast cancer cells to PARP inhibitors. Oncotarget 2016;7:7701-14.
63. Lin ZP, Ratner ES, Whicker ME, Lee Y, Sartorelli AC. Triapine disrupts CtIP-mediated homologous recombination repair and sensitizes ovarian cancer cells to PARP and topoisomerase inhibitors. Mol Cancer Res 2014;12:381-93.
64. Sun C, Fang Y, Labrie M, Li X, Mills GB. Systems approach to rational combination therapy: PARP inhibitors. Biochem Soc Trans 2020;48:1101-8.
65. Zatreanu D, Robinson HMR, Alkhatib O, et al. Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance. Nat Commun 2021;12:3636.
66. McCabe N, Turner NC, Lord CJ, et al. Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition. Cancer Res 2006;66:8109-15.
67. Gogola E, Duarte AA, de Ruiter JR, et al. Selective loss of PARG restores PARylation and counteracts PARP inhibitor-mediated synthetic lethality. Cancer Cell 2018;33:1078-1093.e12.
